Cite
Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.
MLA
Müller, Cristina, et al. “Terbium-161 for PSMA-Targeted Radionuclide Therapy of Prostate Cancer.” European Journal of Nuclear Medicine & Molecular Imaging, vol. 46, no. 9, Aug. 2019, pp. 1919–30. EBSCOhost, https://doi.org/10.1007/s00259-019-04345-0.
APA
Müller, C., Umbricht, C. A., Gracheva, N., Tschan, V. J., Pellegrini, G., Bernhardt, P., Zeevaart, J. R., Köster, U., Schibli, R., & van der Meulen, N. P. (2019). Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. European Journal of Nuclear Medicine & Molecular Imaging, 46(9), 1919–1930. https://doi.org/10.1007/s00259-019-04345-0
Chicago
Müller, Cristina, Christoph A. Umbricht, Nadezda Gracheva, Viviane J. Tschan, Giovanni Pellegrini, Peter Bernhardt, Jan Rijn Zeevaart, Ulli Köster, Roger Schibli, and Nicholas P. van der Meulen. 2019. “Terbium-161 for PSMA-Targeted Radionuclide Therapy of Prostate Cancer.” European Journal of Nuclear Medicine & Molecular Imaging 46 (9): 1919–30. doi:10.1007/s00259-019-04345-0.